A Unique Environment to Develop Innovative Therapeutics
NETRIS Pharma is the first spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon – CRCL – (Lyon, France) and benefits from the exceptional environment of this world’s renowned comprehensive center dedicated to cancer care, education and research.


Our news
05/16/2022
Meet with NETRIS Pharma at the Bio International Convention in San Diego CA (June 13-16 2022)
05/09/2022
NETRIS Pharma is excited to participate to the "A Vos Baskets" challenge !
12/16/2021
NETRIS PHARMA SELECTED BY THE EUROPEAN INNOVATION COUNCIL ACCELERATOR AMONG THE MOST INNOVATIVE STARTUPS AND SMES COMPANIES IN EUROPE !
Our publications
04/04/2022
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer
03/11/2022
Δ40p53 isoform up-regulates netrin-1/UNC5B expression and potentiates netrin-1 pro-oncogenic activity
03/11/2022
Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma Progression
A Strategic Focus on Intellectual Property Rights
As the world pioneer and leader biotech company targeting ligands of Dependence Receptors, NETRIS Pharma has built and is periodically reinforcing a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach and activity.
Our partners
NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate partners.
Clinical
Corporate
Research

